GlassScriptPhysician profile
Molly L Springate
NPI 1932648128
$2,196.72
in general payments reported to CMS, 2019-2025
27 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $453 · 2023: $644 · 2024: $689 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,744.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $539.14 | 2022-2025 | |
| Glaxosmithkline, LLC. | $225.82 | 2022-2023 | Shingrix, Arexvy |
| Pfizer INC. | $213.95 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $160.56 | 2022-2024 | Spravato |
| Novo Nordisk INC | $140.70 | 2023-2025 | Wegovy |
| Lilly USA, LLC | $130.30 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Currax Pharmaceuticals LLC | $108.70 | 2022-2025 | Contrave, Onzetra Xsail, Nexlizet |
| Astrazeneca Pharmaceuticals LP | $100.30 | 2022-2025 | Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $68.69 | 2022-2024 | Rexulti, Nuedexta |
| Axsome Therapeutics, INC. | $53.49 | 2023-2024 | Auvelity |
| Ibsa Pharma INC. | $48.15 | 2023-2024 | Tirosint, Licart, Licart |
| Acella Pharmaceuticals, LLC | $44.27 | 2024-2025 | NP Thyroid 60 |
| Vivus LLC | $41.59 | 2023-2024 | Qsymia |
| Antares Pharma, INC. | $37.51 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Amgen INC. | $37.29 | 2023-2024 | Krystexxa, Repatha, Otezla |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $32.19 | 2023 | Intellis Adaptivestim, Venaseal |
| Daiichi Sankyo INC. | $26.42 | 2024 | Injectafer |
| Teva Pharmaceuticals USA, INC. | $26.06 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.10 | 2022 | |
| Halozyme INC | $21.73 | 2023 | |
| Mayne Pharma Commercial LLC | $19.90 | 2025 | |
| Astellas Pharma US INC | $18.35 | 2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $17.38 | 2022 | |
| Exact Sciences Corporation | $16.00 | 2025 | Cologuard Collection Kit |
| Alkermes, INC. | $15.74 | 2023 | Vivitrol |
| Azurity Pharmaceuticals, INC. | $15.57 | 2023 | Adthyza |
| Exeltis, USA INC. | $14.82 | 2025 | Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Springate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.